Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer

Phosphatidylinositol-5-phosphate 4-kinase type IIa (PIP4K2A); PIP4K2B

Mouse and cell culture studies suggest inhibiting PIP4K2A and PIP4K2B could help treat p53- breast cancer. In human breast cancer samples, deletion of TP53, which encodes p53, increased PIP4K2B levels compared with no alteration. In cultured TP53-deficient breast cancer cells and mouse xenografts, knockdown of both PIP4K2A and PIP4K2B decreased cancer cell proliferation and tumor formation compared with no alteration. In Tp53-deficient mice, homozygous deletion of Pip4k2a and heterozygous deletion of Pip4k2b decreased tumor formation. Next steps could include studies to understand the relationship between PIP4K2A and PIP4K2B and glucose metabolism in tumors.

SciBX 6(48); doi:10.1038/scibx.2013.1377
Published online Dec. 19, 2013

Patent and licensing status unavailable

Emerling, B.M. et al. Cell;
published online Nov. 7, 2013;
doi:10.1016/j.cell.2013.09.057
Contact: Lewis C. Cantley, Harvard Medical School, Boston, Mass.
e-mail:
lcantley@med.cornell.edu